The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development.
GLOSTRUP, Denmark, March 24, 2015 (GLOBE NEWSWIRE) -- Dako, an Agilent
Technologies company and a worldwide provider of cancer diagnostics,
today announced a new Master Collaboration Agreement with Amgen Inc., a
leading biotechnology company.
The expanded collaboration will allow both companies to benefit from
knowledge-sharing within the field of drug-diagnostic research and
development in general, and in relation to companion diagnostic
products in particular. This collaboration is important in the area of
personalized medicine, where targeted treatments and companion
diagnostics can help identify patients for whom a particular treatment
may work, leading to improved patient care and more manageable
"We are proud to both continue and broaden our multi-year partnership
with Amgen," said Jacob Thaysen, president of Agilent's Diagnostics and
Genomics Group. "Together we will continue our work in the development
of high-quality companion diagnostic products to enable physicians and
pathologists to identify cancer patients who are more likely to respond
to a specific therapy."
Today's announcement follows several other collaborative agreements in
the companion diagnostics area. Agilent's Dako business has
partnerships with several top-tier pharma companies for the development
of companion diagnostics. Its track record and experience in companion
diagnostic development continues to attract new partners, as well as
add new projects with current partners.
The financial details of the agreement were not disclosed.
About Agilent Technologies and Dako Agilent Technologies Inc. (NYSE:A),
a global leader in life sciences, diagnostics and applied chemical
markets, is the premier laboratory partner for a better world. Agilent
works with customers in more than 100 countries, providing instruments,
software, services and consumables for the entire laboratory workflow.
Agilent generated revenues of $4.0 billion in fiscal 2014. The company
employs about 12,000 people worldwide. In 2012, Agilent acquired Dako,
a well-known provider of reagents, instruments, software and expertise
to make accurate diagnoses and determine the most effective treatment
for cancer patients. Information about Agilent is available at
and information about Dako is available at